What Does it Cover?
Single molecule counting (SMC®) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers, or assist in therapeutic development with an improved view of efficacy, safety & time course studies. When time and resources are limited, we offer a comprehensive portfolio of Custom Services supported by a scientific team with core expertise in SMC® technology. Learn how our team will partner with you to develop a project specific to your requirements, whether that is fit-for-purpose sample testing, biomarker analysis using our current SMC® immunoassays, or the development and manufacture of an immunoassay for your novel target of interest. Learn how we work with our clients to define and tailor a customized project plan that includes milestone driven tasks, collaborative data review, and progress reports. Whether your focus is to expedite your clinical research or to transfer a method to a CRO, we will show you how our services can help you accelerate programs from discovery into clinical trials.
What Will You Learn?
- General background on Single Molecule Counting (SMC®) technology
- How SMC®technology enables quantification of low concentration biomarkers for improved stratification of sample populations, drug development, and new biomarker discovery
- Custom Assay & Sample Testing Services: Discussion on the full range of services available
Who Should Watch?
- Researchers interested in biomarker discovery
- Therapeutic Development Scientists
- Protein biochemists
- Life science researchers
- Molecular biologists
Request Info on SMC® Technology
For Research Use Only. Not For Use In Diagnostic Procedures.
Speaker
Sarah Hamren
{hcompany}
Former Head of Custom Assays & Sample Testing Group
Sarah Hamren was the former head of the SMC® Custom Assay and Sample Testing group until 2021. She has over 30 years of experience in biopharma research and development and her past experience includes work at Chiron Corporation, Bayer Corporation’s Biotechnology division, Tethys Bioscience, and Singulex® Inc. before joining us. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s experience effectively partnering with a broad array of clients has culminated in hundreds of successful biomarker assay development projects.
Protein biology
- Protein quantitation
Duración:36min
Idioma:English
Sesión 1:presentado May 23, 2018
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?